Healthcare and Life Sciences Business Outlook: 2022 – Healthcare Economist

My colleagues at FTI have a new white paper out surveying well being care leaders on tendencies to anticipate in 2022. The information come from a survey of 251 senior determination makers working in company
communications, investor relations, public affairs, enterprise improvement, R&D and advertising for healthcare and life sciences corporations within the U.S. Some key findings:

Drug pricing

Greater than two-thirds (69%) anticipate important coverage adjustments might be made on drug pricing below the Biden Administration over the subsequent 12 months.




Deal-making is anticipated to rise in 2022. Essentially the most important enhance is predicted in healthcare IPO exercise, with 65% (+12% since 2020) anticipating it to be increased in 2022,
and 1 in 4 (24%) anticipating it to be “far increased.” Almost 7 in 10 (65%) anticipate M&A exercise to be increased in 2022, rising +5% from final yr, and majority (57%) additionally foresee increased SPAC
exercise in 2022 than within the earlier 12 months.

Hybrid vs. in-person office

Relating to planning a return to the office, 78% are optimistic {that a}
workable steadiness could be discovered. Firms are, nevertheless, cut up of their strategy, with
49% planning to supply a hybrid working strategy, whereas 43% are contemplating returning to pre-pandemic working.

Related Articles

Back to top button